title: Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
abstract: BACKGROUND
  Hepatitis C virus (HCV) is a chronic infection that disproportionately impacts people living with HIV. In the past, HCV therapy was less effective in individuals with HIV co-infection. However, the advent of direct-acting antivirals has revolutionized HCV treatment with high rates of success in patients both with and without HIV.
  
  
  METHODS
  In this paper, we review the evidence supporting the use of ledipasvir and sofosbuvir (LDV/SOF) for the treatment of HCV in patients with HIV co-infection. Articles searchable on MEDLINE/PubMed were reviewed to provide context for use of LDV/SOF in individuals with HCV and HIV co-infection.
  
  
  CONCLUSIONS
  This treatment is highly effective in achieving HCV cure or sustained virologic response, however further studies need to done to address efficacy of treatment in people with uncontrolled HIV, concerns regarding drug-interactions with antiretroviral therapy, and potential for shorter duration treatment.
authors.affiliation: a Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research , Frederick , MD , USA.
authors.forename: Elana S
authors.initials: ES
authors.lastname: Rosenthal
authors.affiliation: b Division of Clinical Care and Research, Institute of Human Virology , University of Maryland , Baltimore , MD , USA.
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
authors.affiliation: c Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases , National Institutes of Health.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Polis
mesh_terms: D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D060085:Coinfection; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005449:Fluorenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069474:Sofosbuvir / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir
keywords: HIV/HCV co-infection; Hepatitis C virus; direct-acting antivirals; ledipasvir/sofosbuvir